<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04049734</url>
  </required_header>
  <id_info>
    <org_study_id>689</org_study_id>
    <nct_id>NCT04049734</nct_id>
  </id_info>
  <brief_title>Oral Losartan in Prevention of Post-ERCP Paancreatitis</brief_title>
  <official_title>Evaluation of Oral Losartan in the Prevention of Post-ERCP Pancreatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Oral losartan given in the dose of 50 mg one hour before ERCP was studied in the prevention
      of post ERCP pancreatitis in 50 patients indicated for ERCP in comparison with another 50
      patients underwent ERCP without receiving oral losartan.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2015</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with development of acute pancreatitis</measure>
    <time_frame>24 hours</time_frame>
    <description>Number of participants with development of abdominal pain and elevated serum amylase and/or lipase</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Post-ERCP Acute Pancreatitis</condition>
  <arm_group>
    <arm_group_label>patients received the oral losartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50 patients with obstructive jaundice indicated for ERCP and received oral losartan 1 hour before ERCP as a prophylaxis of post-ERCP pancreatitis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>patients didn't receive the oral losartan</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>50 patients with obstructive jaundice indicated for ERCP and didn't receive any prophylactic drugs</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oral losatan</intervention_name>
    <description>50 mg of oral losartan one hour before the ERCP once</description>
    <arm_group_label>patients received the oral losartan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any adult patient indicated for ERCP

          -  Patients with obstructive jaundice.

          -  Patients with dilated intra-hepatic or extra-hepatic bile ducts due to malignant or
             benign lesions.

        Exclusion Criteria:

          -  Patients refusing to undergo the procedure or signing the informed consent

          -  Patients with clinically evident acute pancreatitis before the procedure

          -  Patients with previous endoscopic or surgical sphincterotomy

          -  Patients with current use of losartan

          -  Patients who are allergic or hypersensitive to losartan or hydro soluble contrast
             solutions

          -  Patients receiving NSAIDS within a week prior to assessment

          -  Patients with severe co-morbid conditions as cardiovascular disease, renal failure or
             decompensated liver cirrhosis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 3, 2019</study_first_submitted>
  <study_first_submitted_qc>August 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 8, 2019</study_first_posted>
  <last_update_submitted>August 8, 2019</last_update_submitted>
  <last_update_submitted_qc>August 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Shereen Abou Bakr Saleh</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

